The Latest Breaking News from Pfizer Inc

Rising chronic diseases, an aging population, and surging healthcare spending should boost the pharmaceutical industry’s growth prospects. Moreover, the pharmaceutical industry usually holds up well during market downturns due to relatively inelastic demand for their products and services. Therefore, fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

Americans will get a clearer idea of how often they’ll roll up their sleeves for COVID-19 shots when advisers to U.S. regulators meet Thursday to discuss an immunization schedule that looks more like the one used for flu.

Biopharmaceutical company Pfizer (PFE) is committed to executing its strategies to deliver breakthroughs to patients worldwide. The company saw a solid operational performance in the last reported quarter and raised its full-year 2022 outlook. Given PFE’s strong fundamentals and reliable dividends, this stock could be an ideal long-term investment. Read…

Instead of a Santa Claus rally, the market continues to experience volatility at the end of the year with uncertainties surrounding the reopening of the Chinese economy and a looming recession due to seemingly unending interest rate hikes. Given this backdrop, loading up on fundamentally strong stocks Walmart (WMT), Pfizer…

Given that COVID-19 is here to stay for the foreseeable future, investors could still benefit from their investments in companies that saw record-breaking sales during the pandemic’s height because of the effectiveness of their products in fighting the virus. With the potential resurgence of COVID-19 in several countries, Pfizer (PFE)…

Despite rampant market volatility, Goldman Sachs expects the U.S. economy to avoid a recession. However, as uncertainties remain, medical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY), which pay reliable dividends, could be ideal buys to ensure a steady income stream. Keep reading….

Amid rising global medical needs, the pharmaceutical industry is expected to witness robust growth in the coming years. Moreover, healthcare is considered relatively resilient amid market downturns. So, given the economic uncertainties, investors could consider buying quality pharmaceutical stocks such as Pfizer (PFE), Novartis (NVS), and Bristol-Myers Squibb (BMY) this…

Along with an interest rate hike of 50 bps at the FOMC meeting last week, the Fed officials signaled to continue raising rates through next year, with no expectations to cut rates until 2024. The Fed’s hawkish stance and rising recessionary fears have dampened investor sentiment lately. Given the backdrop,…

The Fed announced a 50-bps rate hike this week, stepping down from its 75-bps raises for four consecutive times. With cooling inflation and reduced interest rate hikes, the economy might succeed in avoiding a recession. However, as the market conditions are expected to remain uncertain with the Fed intending to…